Piroxicam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Piroxicam: From Rheumatoid Arthritis to Juvenile Idiopathic Arthritis
One-Sentence Summary
Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) originally used for rheumatoid arthritis and osteoarthritis. The TxGNN model’s top-ranked prediction is a rare skeletal and ocular syndrome with no supporting evidence, whereas the only prediction with real literature support is Juvenile Idiopathic Arthritis (JIA), backed by 0 registered clinical trials and 11 publications, mostly dated and several only indirectly related.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, osteoarthritis (from the knowledge graph; no approved-indication text is available from US labels) |
| Predicted New Indication | Colobomatous microphthalmia-rhizomelic dysplasia syndrome (rank 1; no supporting evidence). The best-supported candidate is juvenile idiopathic arthritis (rank 10) |
| TxGNN Prediction Score | 99.996% (rank 1); 99.93% (juvenile idiopathic arthritis) |
| Evidence Level | L5 (rank 1); L3 (juvenile idiopathic arthritis) |
| US Market Status | Cancelled only |
| Number of NDAs | 7 (all ANDA generics, all cancelled) |
| Recommended Decision | Hold (rank 1); Proceed with Guardrails is suggested only for the JIA research question |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, piroxicam is an NSAID that inhibits cyclo-oxygenase (COX-1/COX-2) and reduces prostaglandin-mediated inflammation. This is the same mechanism that underlies its use in rheumatoid arthritis and osteoarthritis.
Top-ranked prediction (colobomatous microphthalmia-rhizomelic dysplasia syndrome): No mechanistic link was identified. This is a rare developmental skeletal and ocular syndrome, and COX inhibition would not be expected to alter its course. The very high score is most likely a knowledge-graph artifact. The same applies to the other top-ranked predictions (brachydactyly-syndactyly syndrome, Hunter-Thompson acromesomelic dysplasia, brachyolmia and related syndromes, pseudoachondroplasia, WHIM syndrome). Myosclerosis and rheumatoid nodulosis have at most weak, indirect plausibility.
Best-supported prediction (juvenile idiopathic arthritis): JIA is an inflammatory arthropathy in which NSAIDs are used as symptomatic first-line therapy. The existing literature includes piroxicam head-to-head studies against naproxen in children, as well as pediatric pharmacokinetic data. This is better described as an extension within the same anti-inflammatory class than as a true repurposing. The evidence is also old (1986–1991).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The table covers the juvenile idiopathic arthritis prediction, the only one with literature. It is ordered by evidence priority and lists the 10 most relevant publications.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38680254 | 2024 | Systematic review / network meta-analysis | World J Clin Cases | Compares different NSAIDs for JIA; the abstract states that the optimal approach has not yet been established |
| 33632948 | 2021 | Systematic review / network meta-analysis | Indian Pediatrics | Compares the efficacy and safety of nine NSAIDs in JIA |
| 2957205 | 1987 | Randomized clinical study | Eur J Rheumatol Inflamm | 26 patients aged 3–25 years randomized to piroxicam or naproxen in juvenile rheumatoid arthritis; painful and swollen joint counts decreased significantly |
| 3510686 | 1986 | Multicentre double-blind crossover study | Br J Rheumatol | Piroxicam vs naproxen in 47 children with seronegative juvenile chronic arthritis; no significant difference between the two treatments |
| 1782984 | 1991 | Pharmacokinetic study | Eur J Clin Pharmacol | 10 children with arthritis on piroxicam (about 0.4 mg/kg once daily); mean half-life about 32.6 hours |
| 2185374 | 1990 | Review | Kinderarztl Prax | Overview of drug therapy for juvenile chronic arthritis, including piroxicam |
| 9890680 | 1998 | Long-term follow-up | Clin Rheumatol | Long-term toxicity of antirheumatic and anti-inflammatory drugs in 117 children (general NSAID safety, not piroxicam-specific) |
| 21175420 | 2010 | Review (indirect) | Crit Rev Ther Drug Carrier Syst | NSAID drug delivery systems in arthritis |
| 15456329 | 2004 | Review (indirect) | Drugs | Nabumetone in osteoarthritis and rheumatoid arthritis; not about piroxicam |
| 3539573 | 1986 | Review (indirect) | Drugs | Pirprofen review; piroxicam is mentioned only as a comparator |
US Market Information
All seven authorizations are generic capsules and all are now cancelled. No approved-indication text is available for them.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA210347 (PD-Rx Pharmaceuticals) | Piroxicam | Capsule | Not available |
| ANDA074116 (Bryant Ranch Prepack) | Piroxicam | Capsule | Not available |
| ANDA208340 (Unichem Pharmaceuticals) | Piroxicam | Capsule | Not available |
| ANDA074131 (Teva Pharmaceuticals USA) | Piroxicam | Capsule | Not available |
| ANDA206152 (Micro Labs Limited) | Piroxicam | Capsule | Not available |
Two further cancelled authorizations are not shown: ANDA206136 (Proficient Rx) and ANDA074118 (Bryant Ranch Prepack).
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for safety information.
Contraindication-related conditions (from the knowledge graph, not label text): The drug-disease contraindication links include:
- Cardiovascular: hypertension, congestive heart failure, myocardial infarction, stroke and cerebrovascular disorders, coronary thrombosis, thrombotic disease
- Hepatic and renal: kidney disease, liver disease, acute liver failure, hepatitis, drug-induced liver injury, gallbladder disease
- Gastrointestinal and haematological: active peptic ulcer disease, blood coagulation disease, anaemia and hemoglobinopathy
- Other: substance abuse/dependence, vision disorders and blindness
Drug interactions: The interaction query returned 100 records. The main ones among the first 20 listed are:
- Moderate: acetylsalicylic acid (aspirin), corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), metformin, sulfonylureas (glimepiride, chlorpropamide), aprepitant, mesalazine, balsalazide, potassium citrate and bicarbonate, and bowel-preparation agents (picosulfuric acid, polyethylene glycol with electrolytes)
- Minor: H2 blockers (famotidine, ranitidine, cimetidine) and linaclotide
Conclusion and Next Steps
Decision: Hold for the top-ranked predictions. For juvenile idiopathic arthritis, only a limited research question (Proceed with Guardrails) is suggested.
Rationale:
- The highest-scoring predictions are rare genetic skeletal, ocular, or immune syndromes with no trials, no literature, and no plausible COX-inhibition rationale, so they look like model artifacts (L5).
- Juvenile idiopathic arthritis has some support (L3), but the evidence is dated, there are no registered trials, and it is essentially an extension of the existing NSAID class use rather than a new repurposing. All US generic authorizations are cancelled, which limits practical availability.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data from DrugBank
- A review of current JIA guidelines and newer therapies to judge whether piroxicam adds value over available NSAIDs
- A pediatric safety assessment, given the cardiovascular, gastrointestinal, hepatic, and renal contraindication signals
- Confirmation of current commercial availability in the US
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.